Despite major interest in this pathway for cancer drug discovery, no drugs have yet been approved that act specifically against PI3K or its downstream regulator, AKT. However, several drugs that ...

肿瘤治疗电场（TTFields）已用于治疗多种癌症，但部分患者疗效不佳。为探究原因，研究人员开展 TTFields 与 PI3K/AKT 通路关系的研究。结果发现 PI3K/AKT 通路参与癌细胞对 TTFields 的反应，抑制该通路可增敏。这为提升 TTFields 疗效提供新思路。

宫颈癌 (CC)仍是全球女性癌症死亡的主要原因，部分患者会出现原发性肿瘤早期转移，但其机制尚未阐明。研究发现E3泛素连接酶家族成员RING box蛋白-1 (RBX1)在90例CC患者活检组织中异常高表达，且在转移病例中表达更为显著。体外实验显示，在Hela细胞中过表达RBX1可显著增强细胞迁移和侵袭能力，而敲低RBX1则产生相反效果。机制研究表明，RBX1通过调控基质金属蛋白酶 ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

A new review was published in Oncotarget, Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." In this review article, Dinara Ryspayeva and colleagues from Brown ...